Inogen Inc. (NASDAQ:INGN) saw an uptick in trading volume on Thursday . 232,204 shares were traded during mid-day trading, a decline of 9% from the previous session’s volume of 254,080 shares.The stock last traded at $51.23 and had previously closed at $51.75.

A number of research firms have weighed in on INGN. JPMorgan Chase & Co. began coverage on shares of Inogen in a research report on Wednesday. They issued an “overweight” rating for the company. Leerink Swann reissued an “outperform” rating and issued a $60.00 price objective on shares of Inogen in a research report on Wednesday, June 8th. Needham & Company LLC reissued a “strong-buy” rating and issued a $58.00 price objective (up from $47.00) on shares of Inogen in a research report on Tuesday, May 10th. Stifel Nicolaus reissued a “buy” rating and issued a $52.00 price objective (up from $46.00) on shares of Inogen in a research report on Tuesday, May 10th. Finally, Piper Jaffray Cos. started coverage on shares of Inogen in a research report on Thursday, March 24th. They issued a “neutral” rating and a $46.00 price objective for the company. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Inogen presently has an average rating of “Buy” and a consensus price target of $52.83.

The company has a 50-day moving average of $49.18 and a 200 day moving average of $42.46. The company has a market cap of $1.01 billion and a price-to-earnings ratio of 86.04.

Inogen (NASDAQ:INGN) last released its earnings results on Monday, May 9th. The medical technology company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by $0.01. During the same period last year, the firm posted $0.08 EPS. The business had revenue of $43 million for the quarter, compared to the consensus estimate of $41.75 million. The firm’s quarterly revenue was up 27.6% on a year-over-year basis. Equities analysts forecast that Inogen Inc. will post $0.60 EPS for the current fiscal year.

In other news, CEO Raymond Huggenberger sold 20,747 shares of the firm’s stock in a transaction on Thursday, June 16th. The shares were sold at an average price of $47.86, for a total transaction of $992,951.42. Following the transaction, the chief executive officer now owns 27,555 shares in the company, valued at approximately $1,318,782.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Matt Scribner sold 4,102 shares of the firm’s stock in a transaction on Thursday, June 16th. The shares were sold at an average price of $47.66, for a total transaction of $195,501.32. Following the transaction, the executive vice president now owns 2,738 shares in the company, valued at approximately $130,493.08. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have added to or reduced their stakes in INGN. Wells Fargo & Company MN increased its position in Inogen by 93.1% in the fourth quarter. Wells Fargo & Company MN now owns 1,002,254 shares of the medical technology company’s stock worth $40,180,000 after buying an additional 483,304 shares in the last quarter. Pembroke Management LTD acquired a new position in Inogen during the fourth quarter worth $10,118,000. Dimensional Fund Advisors LP increased its position in Inogen by 131.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 274,332 shares of the medical technology company’s stock worth $10,998,000 after buying an additional 155,800 shares in the last quarter. First Trust Advisors LP acquired a new position in Inogen during the fourth quarter worth $2,419,000. Finally, Cornerstone Capital Management Holdings LLC. increased its position in Inogen by 29.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 93,441 shares of the medical technology company’s stock worth $3,746,000 after buying an additional 21,141 shares in the last quarter.

Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company offers Inogen One systems, such as Inogen One G3 and G2 that concentrate the air around the patients to offer a single source of supplemental oxygen.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.